While progress has been made in developing disease-modifying therapies for the treatment of autoimmunity, it is increasingly clear that successful therapy will need to reinstate long-lasting immunological tolerance to the targeted self-antigens1, 2, thereby preventing pathogenic CD4+ T-cell responses. This evidence concerns the gene CD4 and Autoimmunity.